• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

J&J’s Acclarent to pay $18m over off-label marketing charges

July 22, 2016 By Fink Densford

GavelJohnson & Johnson (NYSE:JNJ) subsidiary Acclarent will pay $18 million to resolve allegations over false claims submitted to Medicare and other federal health care programs in relation to marketing its Relieva Stratus MicroFlow sinus spacer as a drug-delivery device without FDA clearance.

The company won FDA clearance in 2006 to market the Stratus as a spacer to be used only with saline to maintain sinus openings following surgery, but the government alleged that Acclarent intended for the Stratus to be used as a drug-delivery device, and that the device was designed for the use.

“The FDA approval process serves an important role in ensuring that federal health care participants receive devices that are safe, effective and medically appropriate. We will not permit companies to circumvent that process and put profits over patient safety,” Justice Department civil division head Benjamin Mizer said in a press release.

The government alleged that Acclarent marketed the stratus as a drug delivery device even after a 2007 rejection from the FDA as the company sought to expand the indications. Company employees even trained physicians using a video that demonstrated the device being used with a prescription corticosteroid, according to the government release.

In 2010, Acclarent added a warning to its label regarding the use of the Stratus as a drug delivery device, but the government alleged that the company continued to market the Stratus as a drug delivery device. In May, 2013, Acclarent discontinued all sales of the device and withdrew all FDA marketing clearances for it.

The government further alleged that Acclarent marketed the Stratus as a drug delivery device even after the FDA rejected the company’s 2007 request to expand the approved uses for the Stratus. For example, Acclarent employees trained physicians using a video that demonstrated the Stratus being used with prescription corticosteroid Kenalog-40 and also used a white, milky substance resembling Kenalog-40 when demonstrating the Stratus.

Yesterday, a federal jury convicted 2 former Acclarent executives for the distribution of adulterated and misbranded medical devices, but acquitted them of the felony charges leveled in the case.

Former CEO William Facteau and ex-sales vice president Patrick Fabian were convicted by a jury after a 6-week trial on 10 misdemeanor counts of “introducing adulterated and misbranded medical devices into interstate commerce.” Facteau is now chairman, president & CEO of EarLens, and Fabian was listed as the CCO of NxThera as of 2014.

The jury acquitted both defendants on 10 counts of felony adulteration and misbranding, 3 counts of wire fraud and 1 count of conspiracy. Four of the felony charge initially brought against the pair were dismissed before the case went to trial, according to Steptoe & Johnson, the law firm representing Facteau.

The remaining charges were related to the Relieva Stratus sinus dilation device. Prosecutors alleged that Facteau and Fabian launched the Relieva Stratus device intending it to be used as a steroid delivery device, even after the FDA had specifically refused Acclarent’s request to clear it as a drug-delivery device without further regulatory submissions.

Filed Under: Drug-Device Combinations, Legal News Tagged With: Acclarent Inc., johnsonandjohnson

IN CASE YOU MISSED IT

  • Glooko adds chief strategy officer to chief medical officer’s title
  • Cordis launches 10,000-patient registry for drug-eluting balloon
  • Senseonics opens $50M public offering, $25M private placement with Abbott
  • Study links Abbott CGM use to lower risk of hospitalizations due to heart complications
  • Go-Pen ApS wins FDA nod for user-filled insulin pen

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS